Skip to main content
Contact us
Programs

One platform, multiple applications.

Tempo is advancing MAP™ in surgical reconstruction and wound healing, with additional opportunities in aesthetic dermatology and other regenerative medicine applications.

Conceptual volumetric hydrogel scaffold in a tissue defectSurgical reconstruction

From flat sheets to flowable 3D.

Soft-tissue reconstruction today relies on sheet matrices. MAP™ fills irregular wounds in three dimensions and supports tissue formation throughout the wound volume.

1.75M
Surgical excisions
300k
Complex and exposed-bone cases
$1.3B
Addressable market
Illustrative before view of natural facial skin
Illustrative after view of the same facial skin with subtly softened fine lines

Drag to compare

Regenerative aesthetics

Regeneration without inflammation.

Tempo is exploring regenerative aesthetics with MAP™ formulation variants designed to support dermal remodelling and tissue quality in a clinically credible way.

~7×
Collagen vs. an HA filler*
~10×
Fewer neutrophils vs. a PLLA biostimulator*
$13B
Market, growing ~12% a year

* Preclinical animal data.

* Preclinical results in animal models. Market figures are company estimates from Tempo’s August 2026 presentation.

Pipeline

Six MAP™-based programs.

Tempo’s lead product has completed first-in-human clinical evaluation and has been submitted to the FDA through the De Novo pathway.

Surgical reconstructionRegenerative aestheticsFuture platform programBar length shows the furthest stage reached
Indication
FormulationPreclinicalClin. safetyClin. efficacyMarketing
Status
Derm surgerySurgical
De Novo submitted
Complex skin reconstructionSurgical
Clinic-ready
Fine line wrinklesAesthetics
Clinical safety
Deep contouringAesthetics
Preclinical
Plastic & reconstructionAesthetics
Preclinical
Growth factor accelerationFuture
Early preclinical
Milestones

The road to patients.

Three milestones reached in 2026. The next three years take MAP™ from FDA clearance to commercial launch.

2026
Achieved
  • TT101 submitted to FDA (De Novo)
  • $14.5M financing closed
  • NIH award for MOSAIC II
2027
Targets
  • FDA clearance, TT101
  • TT108 clinical study (OUS)
  • Aesthetics first-in-human (OUS)
2028
Targets
  • 510(k) clearance, next-generation O.R. product
  • Aesthetics feasibility study
2029
Targets
  • Commercial launch, via partnership or future funding
  • Aesthetics pivotal study readout

OUS: outside the United States. Targets are from Tempo’s August 2026 company presentation and may change.